Two Sigma Advisers LP Takes Position in Phreesia, Inc. (NYSE:PHR)

Two Sigma Advisers LP bought a new stake in shares of Phreesia, Inc. (NYSE:PHR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 12,000 shares of the company's stock, valued at approximately $302,000.

Several other large investors also recently bought and sold shares of the business. Charles Schwab Investment Management Inc. grew its stake in shares of Phreesia by 10.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 493,448 shares of the company's stock worth $12,415,000 after acquiring an additional 46,209 shares during the period. Barclays PLC lifted its position in Phreesia by 83.6% during the third quarter. Barclays PLC now owns 94,929 shares of the company's stock valued at $2,163,000 after purchasing an additional 43,225 shares during the period. Deutsche Bank AG boosted its holdings in Phreesia by 95.9% in the fourth quarter. Deutsche Bank AG now owns 57,297 shares of the company's stock worth $1,442,000 after purchasing an additional 28,047 shares during the last quarter. Proficio Capital Partners LLC bought a new stake in Phreesia in the 4th quarter worth approximately $377,000. Finally, M&T Bank Corp grew its position in Phreesia by 56.4% in the 4th quarter. M&T Bank Corp now owns 54,939 shares of the company's stock worth $1,382,000 after purchasing an additional 19,812 shares during the period. 92.10% of the stock is currently owned by institutional investors.

Phreesia Price Performance

NYSE:PHR traded up $0.51 during trading hours on Tuesday, hitting $28.01. 442,438 shares of the stock traded hands, compared to its average volume of 439,834. The company has a market cap of $1.67 billion, a price-to-earnings ratio of -19.05 and a beta of 0.68. Phreesia, Inc. has a 1 year low of $17.07 and a 1 year high of $30.53. The stock has a 50 day moving average price of $24.84 and a 200 day moving average price of $25.63. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.06. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The company had revenue of $115.94 million during the quarter, compared to the consensus estimate of $115.00 million. During the same quarter in the prior year, the firm posted ($0.05) EPS. Phreesia's quarterly revenue was up 14.5% compared to the same quarter last year. Sell-side analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on PHR shares. Citigroup restated a "buy" rating on shares of Phreesia in a research note on Wednesday, May 28th. KeyCorp cut their price target on Phreesia from $30.00 to $28.00 and set an "overweight" rating for the company in a research note on Wednesday, April 16th. Canaccord Genuity Group reduced their price target on shares of Phreesia from $35.00 to $34.00 and set a "buy" rating for the company in a research report on Thursday, May 29th. DA Davidson dropped their price objective on shares of Phreesia from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Finally, Wall Street Zen upgraded shares of Phreesia from a "hold" rating to a "buy" rating in a research report on Sunday, June 1st. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, Phreesia presently has an average rating of "Buy" and an average target price of $31.64.

Insiders Place Their Bets

In other Phreesia news, CFO Balaji Gandhi sold 1,827 shares of the stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $27.46, for a total transaction of $50,169.42. Following the completion of the transaction, the chief financial officer now owns 103,591 shares of the company's stock, valued at $2,844,608.86. This represents a 1.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP David Linetsky sold 4,499 shares of the firm's stock in a transaction dated Wednesday, April 16th. The shares were sold at an average price of $23.73, for a total value of $106,761.27. Following the transaction, the senior vice president now owns 217,239 shares of the company's stock, valued at approximately $5,155,081.47. The trade was a 2.03% decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,474 shares of company stock worth $1,023,208 in the last three months. 5.50% of the stock is owned by company insiders.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.